

# Atorvastatin and endothelial function in systemic lupus erythematosus (SLE) patients

<b>Submission date</b> 12/06/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 21/07/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 21/07/2009	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Gilda Ferreira

**Contact details**  
Pasteur Avenue, 135/1403  
Belo Horizonte  
Brazil  
30150-290  
+55 031 9617 4211  
gildap@terra.com.br

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**  
FAPESP Grant No.: 2003/06738-0

## Study information

**Scientific Title**

Evaluation of the atorvastatin effect on endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8-week controlled trial

**Study objectives**

1. That atorvastatin therapy improves endothelium-dependent arterial dilation in systemic lupus erythematosus (SLE) patients with and without conventional risk factors for atherosclerotic disease
2. That atorvastatin therapy reduces the plasma levels of non-traditional laboratory markers for atherosclerosis in SLE patients

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Local Medical Ethics Committee (Comitê de Ética em Pesquisa da Universidade Federal de Minas Gerais) approved on the 5th November 2003 (ref: ETIC 285/03)

**Study design**

Interventional single-centre non-randomised unblinded temporal series study with a parallel control group

**Primary study design**

Interventional

**Secondary study design**

Non randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Systemic lupus erythematosus (SLE)

**Interventions**

Patients were divided in two groups:

1. The intervention group consisted of 64 patients who received atorvastatin 20 mg/day during 8 weeks. Thirty-three patients in the intervention group had hypertension, dyslipidaemia and/or obesity, while the remaining 31 did not have any conventional risk factors for CHD.
2. The control group comprised 24 SLE patients followed in the same period without atorvastatin (no treatment)

To reinforce and check adherence to the protocol, phone calls or personal contacts were performed 30 days after the beginning the study and atorvastatin tablets were counted at the

end of the study. At baseline and at the end of the 8-week period, all 88 participants underwent complete clinical examination, brachial artery ultrasound and blood sampling for laboratory analysis.

Total duration of treatment: 8 weeks

Total duration of follow-up: 8 weeks

#### Definitions:

1. Family history of CHD: presence of clinical CHD or sudden death in first-degree relatives at ages before 55 years old and 65 years old for men and women, respectively
2. Hypertension: blood pressure higher than 140 mmHg/90 mmHg or current use of antihypertensive medications
3. Obesity: body mass index (BMI) over 30 kg/m<sup>2</sup> and/or presence of abdominal obesity, considered as abdominal circumference above 88 cm
4. Diabetes mellitus: fasting plasma glucose higher than 126 mg/dl or use of oral hypoglycaemic agents or insulin
5. Dyslipidaemia: high density lipoprotein (HDL) cholesterol serum levels less than 40 mg/dl or low density lipoproteins (LDL) cholesterol serum levels greater than 130 mg/dl or total cholesterol serum levels greater than 200 mg/dl or triglyceride serum levels greater than 200 mg/dl
6. Menopause: amenorrhoea for more than one year or use of hormonal replacement therapy

SLE disease activity and damage were measured using SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) and SLICC (The Systemic Lupus International Collaborating Clinics /American College of Rheumatology Damage Index for Systemic Lupus Erythematosus), respectively.

#### Intervention Type

Drug

#### Phase

Phase IV

#### Drug/device/biological/vaccine name(s)

Atorvastatin

#### Primary outcome measure

1. Resting diameter (mm)
2. Resting flow (ml/min)
3. Hyperaemia flow (mL/min)
4. Flow-mediated dilation (%)
5. Glyceryl-trinitrate induced dilation (%)

Measured at baseline and 8 weeks.

Vascular studies were performed at room temperature (25 - 28°C) using high-resolution ultrasound equipment, vascular colour echo-Doppler with flow mapping (ACUSON, Mountain View - California, USA) and multiple-frequency linear 7 MHz transducer. All patients were evaluated between 8:00 and 10:00 am after 12 hours overnight fast. Antihypertensive medication was stopped 24 hours before the study. All exams were performed by the same examiner and with the guidelines for ultrasound assessment of endothelial-dependent flow-

mediated dilation of the brachial artery. Recorded images were later analysed by the examiner without any information on the patient's identification.

### **Secondary outcome measures**

1. Total cholesterol (mg/dl)
2. LDL-cholesterol (mg/dl)
3. HDL-cholesterol (mg/dl)
4. Triglycerides (mg/dl)
5. Creatine phosphokinase (CPK)
6. Homocysteine ( $\mu\text{mol/L}$ )
7. Lipoprotein-a (mg/dL)
8. Endothelin-1 (pg/ml)
9. Cytokines and receptors (tumour necrosis factor-alpha, sTNFR1 and sTNFR2)
10. Chemokines (CL2, CCL3 and CXCL9) serum levels
11. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
12. Anti-DNA antibodies (0 = absent, 1 = present)
13. Anti-oxidised LDL antibodies (0 = absent, 1 = present) and anti-lipoprotein lipase antibodies (0 = absent, 1 = present)
14. Anticardiolipin antibodies (GPL or MPL)

Measured at baseline and 8 weeks.

Laboratory exams were performed according to standard routine techniques. Anti-dsDNA antibodies were detected by indirect immunofluorescence in *Crithidia luciliae*. Homocysteine and lipoprotein-a serum levels were measured by liquid chromatography (reference range less than 15  $\mu\text{mol/L}$ ) and immunonephelometry (Dade Behring, reference range less than 30 mg/dl), respectively. The concentration of cytokines, chemokines, endothelin-1, anti-DNA antibodies, anti-oxidised LDL antibodies, and anti-lipoprotein lipase antibodies, anticardiolipin antibodies were determined by enzyme immunoassay. Anticardiolipin antibodies were considered positive when higher than 20 GPL or 11 MPL.

### **Overall study start date**

21/07/2004

### **Completion date**

23/02/2006

## **Eligibility**

### **Key inclusion criteria**

1. Female
2. SLE according to the American College of Rheumatology revised classification criteria
3. Disease diagnosis equal or greater than 1 year
4. Aged above 18 years old
5. Regular menstruation

### **Participant type(s)**

Patient

### **Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Female

**Target number of participants**

88 patients with SLE

**Key exclusion criteria**

1. Current or past use of hypolipidemic drugs in the last six months
2. Menopausal women
3. Diabetes mellitus
4. Serum creatinine above 1.2 mg/dl
5. Pregnancy
6. Smoking status (last 12 months)
7. Family history of coronary heart disease (CHD)
8. Skeletal myopathic disease and/or elevated creatinine phosphokinase
9. Hepatic disease
10. Ciclosporin use

**Date of first enrolment**

21/07/2004

**Date of final enrolment**

23/02/2006

**Locations****Countries of recruitment**

Brazil

**Study participating centre**

Pasteur Avenue, 135/1403

Belo Horizonte

Brazil

30150-290

**Sponsor information****Organisation**

State of São Paulo Research Foundation (FAPESP) (Brazil)

**Sponsor details**

R. Pio XI, 1500 - Alto da Lapa  
São Paulo  
Brazil  
05468-901  
+55 11 3838 4000  
converse2@fapesp.br

**Sponsor type**

Research organisation

**Website**

<http://www.fapesp.br>

**ROR**

<https://ror.org/02ddkpn78>

## Funder(s)

**Funder type**

University/education

**Funder Name**

Federal University of Minas Gerais (Brazil) - Rheumatology Division; Board of Education, Research and Extension (DEPE) (ref: 078/03)

**Funder Name**

Federal University of São Paulo-Escola Paulista de Medicina (Brazil) - Rheumatology Division

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[Results article](#)

results

01/10/2007

Yes

No